SEP-631 (MRGPRX2)
Chronic Spontaneous Urticaria; Other mast cell diseases
Phase 2Active (Initial strategy outlined)
Key Facts
Indication
Chronic Spontaneous Urticaria; Other mast cell diseases
Phase
Phase 2
Status
Active (Initial strategy outlined)
Company
About Septerna
Septerna's mission is to unlock the vast therapeutic potential of G protein-coupled receptors (GPCRs), a historically productive but still largely underexploited target class. The company has achieved rapid progress, advancing its wholly-owned lead programs into Phase 2 and Phase 1 clinical trials, powered by its industrial-scale Native Complex Platform®. Its strategy combines internal development of high-value, biomarker-driven programs with selective partnerships for complex indications, aiming to deliver a portfolio of novel, oral, disease-modifying medicines.
View full company profile